UzbekistanTuberculosis profile
Population  2015 30 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.6 (2.3–3) 8.8 (7.6–10)
Mortality (HIV+TB only) 0.32 (0.19–0.5) 1.1 (0.62–1.7)
Incidence  (includes HIV+TB) 24 (17–31) 79 (57–105)
Incidence (HIV+TB only) 1.2 (0.74–1.7) 3.9 (2.5–5.7)
Incidence (MDR/RR-TB)** 10 (7.6–12) 33 (25–40)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.95 (0.29–1.6) 9 (5.3–13) 9.9 (5.6–14)
Males 1.4 (0.82–1.9) 12 (9–16) 14 (9.9–18)
Total 2.3 (1.5–3.1) 21 (17–25) 24 (17–31)
TB case notifications, 2015  
Total cases notified 19 055
Total new and relapse 16 315
          - % tested with rapid diagnostics at time of diagnosis 24%
          - % with known HIV status 80%
          - % pulmonary 87%
          - % bacteriologically confirmed among pulmonary 34%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 69% (52–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.13 (0.09–0.18)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 841 6%
          - on antiretroviral therapy 409 49%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  5 800
(4 900–6 600)
Estimated % of TB cases with MDR/RR-TB 24% (18–30) 63% (54–71)  
% notified tested for rifampicin resistance 28% 78% 7 558
MDR/RR-TB cases tested for resistance to second-line drugs   1 978
Laboratory-confirmed cases MDR/RR-TB: 2 149, XDR-TB: 147
Patients started on treatment **** MDR/RR-TB: 2 149, XDR-TB: 147
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 87% 16 328
Previously treated cases, excluding relapse, registered in 2014 81% 3 947
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 53% 2 647
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 40%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
78% (71–85)
TB financing, 2016  
National TB budget (US$ millions) 105
Funding source: 81% domestic, 19% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data